surmount-1 tirzepatide weight loss percent nejm 2022 Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity Semaglutide and Cardiovascular Outcomes in

The more likely drivers are indirect: nausea, reflux, reduced food intake, dehydration, anxiety, low glucose in higher-risk medication combinations, or an existing sleep disorder becoming more noticeable

If two million anti-obesity GLP-1 scripts for weight loss get initiated annually, it will take 14 years to acquire the 11% of long-term eligible heavy users out there while burning through many more who are not committed to the regimen required

Some studies have looked at glycinate and taurate for mood support, but the data is mixed

The less frequent need for injections can mean that users do not develop the same level of comfort or routine, which may influence their overall experience and adherence